These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22233411)

  • 1. Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles.
    Bruno R; Sacchi P; Cima S; Maiocchi L; Novati S; Filice G; Fagiuoli S
    J Viral Hepat; 2012 Jan; 19 Suppl 1():33-6. PubMed ID: 22233411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.
    Foster GR
    Drugs; 2010; 70(2):147-65. PubMed ID: 20108989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).
    Silva M; Poo J; Wagner F; Jackson M; Cutler D; Grace M; Bordens R; Cullen C; Harvey J; Laughlin M
    J Hepatol; 2006 Aug; 45(2):204-13. PubMed ID: 16780997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C.
    Rumi M; Aghemo A; Prati GM
    J Viral Hepat; 2012 Jan; 19 Suppl 1():37-41. PubMed ID: 22233412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis C.
    Noureddin M; Ghany MG
    Gastroenterol Clin North Am; 2010 Sep; 39(3):649-58. PubMed ID: 20951922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of peginterferons.
    Zeuzem S; Welsch C; Herrmann E
    Semin Liver Dis; 2003; 23 Suppl 1():23-8. PubMed ID: 12934165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
    Berak H; Laskus T; Kołakowska-Rządzka A; Wasilewski M; Stańczak JJ; Bardadin K; Walewska-Zielecka B; Horban A
    Adv Med Sci; 2014 Sep; 59(2):261-5. PubMed ID: 25117425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin.
    Fried MW; Hadziyannis SJ
    Semin Liver Dis; 2004; 24 Suppl 2():47-54. PubMed ID: 15346246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
    Turnes J; Romero-Gómez M; Planas R; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Rubio-Terrés C; Ventayol P
    Gastroenterol Hepatol; 2013 Nov; 36(9):555-64. PubMed ID: 24119723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.
    Marcellin P; Forns X; Goeser T; Ferenci P; Nevens F; Carosi G; Drenth JP; Serfaty L; De Backer K; Van Heeswijk R; Luo D; Picchio G; Beumont M
    Gastroenterology; 2011 Feb; 140(2):459-468.e1; quiz e14. PubMed ID: 21034744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.
    Rustgi VK; Esposito S; Hamzeh FM; Shiffman ML
    Aliment Pharmacol Ther; 2008 Mar; 27(5):433-40. PubMed ID: 18081737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylation of interferon alfa: structural and pharmacokinetic properties.
    Pedder SC
    Semin Liver Dis; 2003; 23 Suppl 1():19-22. PubMed ID: 12934164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study.
    Bruno R; Sacchi P; Ciappina V; Zochetti C; Patruno S; Maiocchi L; Filice G
    Antivir Ther; 2004 Aug; 9(4):491-7. PubMed ID: 15456079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD).
    Reddy KR
    Semin Liver Dis; 2004; 24 Suppl 2():33-8. PubMed ID: 15346244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
    JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated interferons.
    Baker DE
    Rev Gastroenterol Disord; 2001; 1(2):87-99. PubMed ID: 12120178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responses to peginterferon alfa-2a vs alfa-2b plus ribavirin in a Mexican population with chronic hepatitis C.
    Sandoval-Ramirez JL; Mata-Marín JA; Huerta García G; Gaytán-Martínez JE
    J Infect Dev Ctries; 2015 Mar; 9(3):267-73. PubMed ID: 25771464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.